Literature DB >> 10421407

Establishing and characterizing a CD30-positive cell line harboring HHV-8 from a primary effusion lymphoma.

H Katano1, Y Hoshino, Y Morishita, T Nakamura, H Satoh, A Iwamoto, B Herndier, S Mori.   

Abstract

Primary effusion lymphoma (PEL, or body-cavity-based lymphoma [BCBL]) is a new subtype of non-Hodgkin's lymphoma in which tumor cells locate in the body cavity exclusively. PEL/BCBL is widely accepted as one of the neoplastic complications of AIDS, associated mostly with human herpesvirus 8 (HHV-8/Kaposi's sarcoma-associated herpesvirus [KSHV]) and Epstein-Barr virus (EBV). We established and characterized a PEL cell line named TY-1 from a 47-year-old patient with AIDS. TY-1 exhibits indeterminate immunophenotype, expressing CD45 and CD30 cell surface antigens but not expressing B- or T-cell markers. Cytogenetic analysis revealed the representative karyotype of 50,XYq-,+7,+8,+11,+15. Southern blot analysis demonstrated HHV-8 and EBV genomes in the original tumor cells obtained from the pericardial effusion, while HHV-8 but not EBV was detected in TY-1 using PCR or Southern blot analysis. Tetradecanylphorbol acetate treatment induced some TY-1 cells to proceed to the reproductive phase. This cell line may be an useful tool for research on PEL and HHV-8.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10421407

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  22 in total

1.  Phosphatase and tensin homolog on chromosome 10 is phosphorylated in primary effusion lymphoma and Kaposi's sarcoma.

Authors:  Debasmita Roy; Dirk P Dittmer
Journal:  Am J Pathol       Date:  2011-08-03       Impact factor: 4.307

Review 2.  Understanding pathogenetic aspects and clinical presentation of primary effusion lymphoma through its derived cell lines.

Authors:  Antonino Carbone; Ethel Cesarman; Annunziata Gloghini; Hans G Drexler
Journal:  AIDS       Date:  2010-02-20       Impact factor: 4.177

3.  High expression of HHV-8-encoded ORF73 protein in spindle-shaped cells of Kaposi's sarcoma.

Authors:  H Katano; Y Sato; T Kurata; S Mori; T Sata
Journal:  Am J Pathol       Date:  1999-07       Impact factor: 4.307

4.  Restoring PU.1 induces apoptosis and modulates viral transactivation via interferon-stimulated genes in primary effusion lymphoma.

Authors:  H Goto; R Kariya; E Kudo; Y Okuno; K Ueda; H Katano; S Okada
Journal:  Oncogene       Date:  2017-05-08       Impact factor: 9.867

Review 5.  Human herpes virus 8-negative primary effusion lymphoma in a patient with a ventriculoperitoneal shunt tube.

Authors:  E Ashihara; C Shimazaki; H Hirai; T Inaba; G Hasegawa; S Mori; M Nakagawa
Journal:  Int J Hematol       Date:  2001-10       Impact factor: 2.490

6.  Tumor suppressor genes FHIT and WWOX are deleted in primary effusion lymphoma (PEL) cell lines.

Authors:  Debasmita Roy; Sang-Hoon Sin; Blossom Damania; Dirk P Dittmer
Journal:  Blood       Date:  2011-06-17       Impact factor: 22.113

7.  Human herpesvirus-8 in Kaposi's sarcoma of the conjunctiva in a patient with AIDS.

Authors:  Hiroshi Minoda; Norio Usui; Tetsutaro Sata; Harutaka Katano; Hiromi Serizawa; Shinya Okada
Journal:  Jpn J Ophthalmol       Date:  2006 Jan-Feb       Impact factor: 2.447

8.  Human herpesvirus 8 (HHV8) sequence variations in HHV8 related tumours in Okinawa, a subtropical island in southern Japan.

Authors:  K Kamiyama; T Kinjo; K Chinen; T Iwamasa; H Uezato; J-I Miyagi; N Mori; N Yamane
Journal:  J Clin Pathol       Date:  2004-05       Impact factor: 3.411

9.  Integration of HIV-1 caused STAT3-associated B cell lymphoma in an AIDS patient.

Authors:  Harutaka Katano; Yuko Sato; Satomi Hoshino; Natsuo Tachikawa; Shinichi Oka; Yasuyuki Morishita; Takaomi Ishida; Toshiki Watanabe; William N Rom; Shigeo Mori; Tetsutaro Sata; Michael D Weiden; Yoshihiko Hoshino
Journal:  Microbes Infect       Date:  2007-09-14       Impact factor: 2.700

10.  Establishment of a CD4-positive cell line from an AIDS-related primary effusion lymphoma.

Authors:  Hiroki Goto; Yuki Kojima; Hirokazu Nagai; Seiji Okada
Journal:  Int J Hematol       Date:  2013-04-21       Impact factor: 2.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.